Diagnostic antibodies and antigens for multiple disease testing: thioredoxin reductase (TrxR), Amphetamines (AMP), Buprenorphine (Bup), Benzoditezite (BZO), Synthetic cannabinoid (K2), 3,4-Methyl​enedioxy​methamphetamine (MDMA)


Thioredoxin (Trx) and thioredoxin reductase (TrxR) plus NADPH, comprising the thioredoxin system, has a large number of functions in DNA synthesis, defense against oxidative stress and apoptosis or redox signaling with reference to many diseases such as cancer, viral disease, ischaemia– reperfusion injury, cardiac conditions, aging, premature birth and newborn physiology. GENEMEDI produces core diagnostic ingredients such as thioredoxin reductase and so on to test multiple disorders using ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT Kit.

Classification: TrxR AMP Bup BZO K2 MDMA



thioredoxin reductase (TrxR)

Cat No. Species Biomarker Disease Cat No.of Antigen Bioactivity validation of Antigen Cat No.of Antibodies Bioactivity validation of Antibodies Order
GMP-h-TrxR Human thioredoxin reductase (TrxR) cancer, viral disease, ischaemia– reperfusion injury, cardiac conditions, aging, premature birth GMP-h-TrxR-Ag01:
Recombinant human TrxR Protein
thioredoxin reductase (TrxR) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in TrxR level test of Multiple disease(cancer, viral disease, ischaemia– reperfusion injury, cardiac conditions, aging, premature birth) and related syndrome evaluation. GMP-h-TrxR-Ab01
GMP-h-TrxR-Ab02:
Anti-human TrxR mouse monoclonal antibody(mAb)
Human thioredoxin reductase (TrxR) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other thioredoxin reductase (TrxR) antibodies in TrxR level test of Multiple disease (cancer, viral disease, ischaemia– reperfusion injury, cardiac conditions, aging, premature birth) and related syndrome evaluation. Picture loading failed.



Amphetamines (AMP)

Cat No.SpeciesBiomarkerDiseaseCat No.of AntigenBioactivity validation of AntigenCat No.of AntibodiesBioactivity validation of AntibodiesOrder
GMP-SMT-223HumanAmphetamines (AMP)ADHD, narcolepsyGMP-SMT-223-Ag01:
BSA-Amphetamines (AMP)
GMP-SMT-223-Ag02:
OVA-Amphetamines (AMP)
Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Amphetamines (AMP), Amphetamines (AMP) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in AMP level test of Multiple disease (ADHD, narcolepsy) and related syndrome evaluation.GMP-SMT-223-Ab01:
Anti-Amphetamines (AMP) mouse monoclonal antibody(mAb)
GMP-SMT-223-Ab02:
Anti-Amphetamines (AMP) human monoclonal antibody(mAb)
Amphetamines (AMP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Amphetamines (AMP) antibodies in AMP level test of Multiple disease (ADHD, narcolepsy) and related syndrome evaluation.Picture loading failed.



Buprenorphine (Bup)

Cat No.SpeciesBiomarkerDiseaseCat No.of AntigenBioactivity validation of AntigenCat No.of AntibodiesBioactivity validation of AntibodiesOrder
GMP-SMT-225HumanBuprenorphine (Bup)GMP-SMT-225-Ag01:
BSA-Buprenorphine (Bup)
GMP-SMT-225-Ag02:
OVA-Buprenorphine (Bup)
Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Buprenorphine (Bup), Buprenorphine (Bup) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in Bup level test of Multiple disease and related syndrome evaluation.GMP-SMT-225-Ab01:
Anti-Buprenorphine (Bup) mouse monoclonal antibody(mAb)
GMP-SMT-225-Ab02:
Anti-Buprenorphine (Bup) human monoclonal antibody(mAb)
Buprenorphine (Bup) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Buprenorphine (Bup) antibodies in Bup level test of Multiple disease and related syndrome evaluation.Picture loading failed.



Benzoditezite (BZO)

Cat No.SpeciesBiomarkerDiseaseCat No.of AntigenBioactivity validation of AntigenCat No.of AntibodiesBioactivity validation of AntibodiesOrder
GMP-SMT-226HumanBenzoditezite (BZO)GMP-SMT-226-Ag01:
BSA-Benzoditezite (BZO)
GMP-SMT-226-Ag02:
OVA-Benzoditezite (BZO)
Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Benzoditezite (BZO), Benzoditezite (BZO) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in BZO level test of Multiple disease and related syndrome evaluation.GMP-SMT-226-Ab01:
Anti-Benzoditezite (BZO) mouse monoclonal antibody(mAb)
GMP-SMT-226-Ab02:
Anti-Benzoditezite (BZO) human monoclonal antibody(mAb)
Benzoditezite (BZO) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Benzoditezite (BZO) antibodies in BZO level test of Multiple disease and related syndrome evaluation.Picture loading failed.



Synthetic cannabinoid (K2)

Cat No.SpeciesBiomarkerDiseaseCat No.of AntigenBioactivity validation of AntigenCat No.of AntibodiesBioactivity validation of AntibodiesOrder
GMP-SMT-233HumanSynthetic cannabinoid (K2)GMP-SMT-233-Ag01:
BSA-Synthetic cannabinoid (K2)
GMP-SMT-233-Ag02:
OVA-Synthetic cannabinoid (K2)
Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Synthetic cannabinoid (K2), Synthetic cannabinoid (K2) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in K2 level test of Multiple disease and related syndrome evaluation.GMP-SMT-233-Ab01:
Anti-Synthetic cannabinoid (K2) mouse monoclonal antibody(mAb)
GMP-SMT-233-Ab02:
Anti-Synthetic cannabinoid (K2) human monoclonal antibody(mAb)
Synthetic cannabinoid (K2) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Synthetic cannabinoid (K2) antibodies in K2 level test of Multiple disease and related syndrome evaluation.Picture loading failed.



3,4-Methyl​enedioxy​methamphetamine (MDMA)

Cat No.SpeciesBiomarkerDiseaseCat No.of AntigenBioactivity validation of AntigenCat No.of AntibodiesBioactivity validation of AntibodiesOrder
GMP-SMT-235Human3,4-Methyl​enedioxy​methamphetamine (MDMA)GMP-SMT-235-Ag01:
BSA-3,4-Methyl​enedioxy​methamphetamine (MDMA)
GMP-SMT-235-Ag02:
OVA-3,4-Methyl​enedioxy​methamphetamine (MDMA)
Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-3,4-Methyl​enedioxy​methamphetamine (MDMA), 3,4-Methyl​enedioxy​methamphetamine (MDMA) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in MDMA level test of Multiple disease and related syndrome evaluation.GMP-SMT-235-Ab01:
Anti-3,4-Methyl​enedioxy​methamphetamine (MDMA) mouse monoclonal antibody(mAb)
GMP-SMT-235-Ab02:
Anti-3,4-Methyl​enedioxy​methamphetamine (MDMA) human monoclonal antibody(mAb)
3,4-Methyl​enedioxy​methamphetamine (MDMA) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other 3,4-Methyl​enedioxy​methamphetamine (MDMA) antibodies in MDMA level test of Multiple disease and related syndrome evaluation.Picture loading failed.






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<